Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTQ: High Dose Tafenoquine with ACTs for Vivax Malaria
NCT05788094Phase 4Recruiting
- Sponsor
- Shoklo Malaria Research Unit
- Start
- Jun 2023
- Primary completion
- Feb 2026
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tafenoquine in Plasmodium vivax malaria (3 arms), sponsored by Shoklo Malaria Research Unit. Primary endpoint: Non-inferiority of ACTs plus Tafenoquine vs Chloroquine plus Tafenoquine at Month 4. Started Jun 2023; status: recruiting.
02
Drugs
tafenoquine
03
Conditions
Plasmodium vivax malaria
Beyond the preview
Go deeper on NCT05788094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05788094.